The Economics of Atopic Dermatitis: From Real-World Burden to Value- Driven Treatment Strategies
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
2
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
3
Timing COVID-19 Protection With VYD2311: Michael Mina, MD, PhD
4
Bumetanide Nasal Spray Targets Heart Failure Edema Before IV
5